Karin Seifert PhD
- Room 285
- LSHTM
- Keppel Street
- London
- WC1E 7HT
- T: ++44 020 7927 2643
Karin Seifert earned a degree in pharmacy from the University of Vienna. She completed a doctoral degree (subject: pharmaceutical chemistry) at the University of Vienna studying structure activity relationhips of alkylphosphocholines against the intestinal parasite Entamoeba histolytica and a potential role of apopotosis in the mode of action of existing therapy. She also holds a Certificate in Pharmacoepidemiology and Pharmacovigilance from LSHTM.
Karin joined LSHTM in 2002 as part of an EC-funded project (MILTLEISH) to work on the anti-leishmanial drug miltefosine. She has since studied mutlidrug therapy for leishmaniasis to provide supportive data for translation into clinical studies, drug delivery systems and the role of macrophages in anti-leishmanial drug treatment in DNDi and Wellcome Trust funded projects.
Affiliation
Teaching
- Organiser of the MSc module "Antimicrobial Chemotherapy"
- Delivering of lectures, practical and tutorial teaching
- Supervision of MSc summer projects
- Contribution to PhD student supervision
Research
Research at LSHTM has included i) resistance and efficacy studies, ii) drug activity evaluation and structure activity relationship (SAR) studies, iii) studies on multidrug and combination chemotherapy, iv) the investigation of drug delivery systems in models of cutaneous and visceral leishmaniasis and v) studies on the role of macrophages in anti-leishmanial drug treatment.
Currently I work on the development of a DNA vaccine against leishmaniasis for both therapeutic and prophylactic appliactions in visceral and cutaneous forms of disease. Here I work and coordinate within an EU funded project (LEISHDNAVAX) with 8 international partners. For further information on LEISHDNAVAX see our website http://www.leishdnavax.org.
I have a strong interest in the biological evidence base for interventions and the predictive value of models used in the discovery and develoment process of anti-parasitic drugs and vaccines.
Research areas
- Drug discovery and development
- Drug resistance
- Parasites
- Vaccines
Disciplines
- Immunology
- Parasitology
- Pharmacology
Disease and Health Conditions
- Leishmaniasis
-
Selected publications
-
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert, K.; Perez-Victoria, F.J.; Stettler, M.; Sánchez-Cañete, M.P.; Castanys, S.; Gamarro, F.; Croft, S.L.;
Int J Antimicrob Agents, 2007; 30(3):229-35
-
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert, K.; Croft, S.L.;
Antimicrob Agents Chemother, 2006; 50(1):73-9
-
Current scenario of drug development for leishmaniasis
Croft, S. L.; Seifert, K.; Yardley, V.
Indian Journal of Medical Research, 2006; 123(3):399-410
-
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use
Perez-Victoria, F. J.; Sanchez-Canete, M. P.; Seifert, K.; Croft, S. L.; Sundar, S.; Castanys, S.; Gamarro, F.
Drug Resistance Updates, 2006; 9(1-2):26-39
-
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)
Seifert, K.; Matu, S.; Javier Perez-Victoria, F.; Castanys, S.; Gamarro, F.; Croft, S. L.
International Journal of Antimicrobial Agents, 2003; 22(4):380-387
-
Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.
Seifert, K.; Duchêne, M.; Wernsdorfer, W.H.; Kollaritsch, H.; Scheiner, O.; Wiedermann, G.; Hottkowitz, T.; Eibl, H.;
Antimicrob Agents Chemother, 2001; 45(5):1505-10
- → View all Karin Seifert's publications
